News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
350,133 Results
Type
Article (19901)
Company Profile (90)
Press Release (330133)
Multimedia
Podcasts (42)
Webinars (6)
Section
Business (89561)
Career Advice (1339)
Deals (17586)
Drug Delivery (69)
Drug Development (61500)
Employer Resources (62)
FDA (9211)
Job Trends (7570)
News (175102)
Policy (15284)
Tag
Academia (1220)
Academic (1)
Accelerated approval (26)
Adcomms (15)
Allergies (104)
Alliances (17886)
ALS (122)
Alzheimer's disease (1152)
Antibody-drug conjugate (ADC) (216)
Approvals (9504)
Artificial intelligence (242)
Autoimmune disease (100)
Automation (13)
Bankruptcy (139)
Best Places to Work (6369)
BIOSECURE Act (8)
Biosimilars (127)
Biotechnology (56)
Bladder cancer (131)
Brain cancer (46)
Breast cancer (554)
Cancer (3730)
Cardiovascular disease (306)
Career advice (1067)
Career pathing (19)
CAR-T (181)
CDC (14)
Celiac Disease (1)
Cell therapy (457)
Cervical cancer (24)
Clinical research (54492)
Collaboration (859)
Company closure (1)
Compensation (458)
Complete response letters (26)
COVID-19 (2292)
CRISPR (45)
C-suite (294)
Cystic fibrosis (103)
Data (5127)
Denatured (3)
Depression (89)
Diabetes (427)
Diagnostics (3531)
Digital health (18)
Diversity (3)
Diversity, equity & inclusion (8)
Drug discovery (138)
Drug pricing (88)
Drug shortages (23)
Duchenne muscular dystrophy (142)
Earnings (55913)
Editorial (23)
Employer branding (11)
Employer resources (53)
Events (56790)
Executive appointments (331)
FDA (11458)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (13)
Funding (852)
Gene editing (102)
Generative AI (17)
Gene therapy (368)
GLP-1 (856)
Government (2483)
Grass and pollen (6)
Guidances (356)
Healthcare (9678)
HIV (45)
Huntington's disease (31)
IgA nephropathy (70)
Immunology and inflammation (182)
Immuno-oncology (38)
Indications (73)
Infectious disease (2459)
Inflammatory bowel disease (129)
Inflation Reduction Act (5)
Influenza (79)
Intellectual property (153)
Interviews (245)
IPO (10252)
IRA (21)
Job creations (1471)
Job search strategy (914)
Kidney cancer (16)
Labor market (52)
Layoffs (301)
Leadership (22)
Legal (2497)
Liver cancer (65)
Longevity (8)
Lung cancer (539)
Lymphoma (321)
Machine learning (15)
Management (17)
Manufacturing (347)
MASH (145)
Medical device (6551)
Medtech (6570)
Mergers & acquisitions (7957)
Metabolic disorders (1052)
Multiple sclerosis (125)
NASH (17)
Neurodegenerative disease (224)
Neuropsychiatric disorders (60)
Neuroscience (2030)
NextGen: Class of 2026 (2661)
Non-profit (1857)
Now hiring (18)
Obesity (505)
Opinion (120)
Ovarian cancer (131)
Pain (135)
Pancreatic cancer (168)
Parkinson's disease (221)
Partnered (18)
Patents (254)
Patient recruitment (334)
Peanut (44)
People (16139)
Pharmaceutical (25)
Pharmacy benefit managers (8)
Phase I (15513)
Phase II (26819)
Phase III (17574)
Pipeline (3834)
Policy (94)
Postmarket research (1587)
Preclinical (5199)
Press Release (30)
Prostate cancer (180)
Psychedelics (33)
Radiopharmaceuticals (171)
Rare diseases (545)
Real estate (1763)
Recruiting (30)
Regulatory (13250)
Reports (37)
Research institute (1197)
Resumes & cover letters (258)
Rett syndrome (24)
RNA editing (8)
RSV (51)
Schizophrenia (118)
Series A (125)
Series B (109)
Service/supplier (5)
Sickle cell disease (72)
Special edition (20)
Spinal muscular atrophy (138)
Sponsored (28)
Startups (1356)
State (2)
Stomach cancer (17)
Supply chain (52)
Tariffs (42)
The Weekly (39)
Vaccines (677)
Venture capital (34)
Weight loss (333)
Women's health (43)
Worklife (12)
Date
Today (59)
Last 7 days (186)
Last 30 days (1191)
Last 365 days (20509)
2026 (1017)
2025 (20492)
2024 (22009)
2023 (24445)
2022 (29984)
2021 (32062)
2020 (30534)
2019 (22702)
2018 (17293)
2017 (17517)
2016 (15334)
2015 (18685)
2014 (13374)
2013 (9816)
2012 (10616)
2011 (11095)
2010 (9732)
Location
Africa (414)
Alabama (45)
Alaska (1)
Arizona (105)
Arkansas (4)
Asia (22739)
Australia (4072)
California (7051)
Canada (2051)
China (797)
Colorado (272)
Connecticut (341)
Delaware (225)
Europe (50723)
Florida (959)
Georgia (232)
Hawaii (1)
Idaho (28)
Illinois (446)
India (35)
Indiana (315)
Iowa (15)
Japan (306)
Kansas (58)
Kentucky (31)
Louisiana (17)
Maine (41)
Maryland (823)
Massachusetts (5089)
Michigan (143)
Minnesota (308)
Mississippi (6)
Missouri (67)
Montana (16)
Nebraska (7)
Nevada (74)
New Hampshire (43)
New Jersey (2092)
New Mexico (4)
New York (1997)
North Carolina (745)
North Dakota (3)
Northern California (3414)
Ohio (166)
Oklahoma (1)
Oregon (20)
Pennsylvania (1347)
Puerto Rico (18)
Rhode Island (18)
South America (571)
South Carolina (19)
Southern California (2864)
Tennessee (69)
Texas (1115)
United States (24528)
Utah (174)
Vermont (1)
Virginia (136)
Washington D.C. (39)
Washington State (558)
West Virginia (1)
Wisconsin (50)
350,133 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 year overall survival
October 10, 2025
·
6 min read
Mergers & acquisitions
GSK Picks Up RAPT for $2.2B as Miels Makes First Move as CEO
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, potentially setting up a competition for GSK with Roche’s Xolair.
January 20, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push
At $9.2 billion, the Cidara acquisition lands among the top 5 largest deals of the year.
November 14, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to go with its original suitor.
November 19, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
·
4 min read
Press Releases
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
January 9, 2026
·
11 min read
Press Releases
FDA Grants Fast Track Designation to Cothera Bioscience’s Zotiraciclib for Treatment of Recurrent High-Grade Glioma with IDH1/2 Mutations
Breakthrough oral CDK9 inhibitor advances care for patients with recurrent high-grade gliomas harboring IDH1/2 mutations
November 26, 2025
·
1 min read
CAR-T
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move
The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 million upfront in January 2024.
October 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes
January 6, 2026
·
5 min read
Press Releases
PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
January 12, 2026
·
9 min read
1 of 35,014
Next
